Journal
VACCINES
Volume 2, Issue 3, Pages 624-641Publisher
MDPI AG
DOI: 10.3390/vaccines2030624
Keywords
viral vector; vaccine; CTL; MVA; adenovirus
Categories
Funding
- Ministry of Education, Science, Sports, Culture of Japan
- Ministry of Health and Welfare of Japan [26462531]
- Grants-in-Aid for Scientific Research [26462531] Funding Source: KAKEN
Ask authors/readers for more resources
Viral vectors are promising tools for gene therapy and vaccines. Viral vector-based vaccines can enhance immunogenicity without an adjuvant and induce a robust cytotoxic T lymphocyte (CTL) response to eliminate virus-infected cells. During the last several decades, many types of viruses have been developed as vaccine vectors. Each has unique features and parental virus-related risks. In addition, genetically altered vectors have been developed to improve efficacy and safety, reduce administration dose, and enable large-scale manufacturing. To date, both successful and unsuccessful results have been reported in clinical trials. These trials provide important information on factors such as toxicity, administration dose tolerated, and optimized vaccination strategy. This review highlights major viral vectors that are the best candidates for clinical use.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available